Stay updated with breaking news from Temporary Authorization. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sustained demand of LUMEVOQ ATUs in France generating €3.1 million revenues in Q1 2022 €36.0 million of cash as of March 31, 2022; runway confirmed to early Q1 2023 Regulatory News: GenSight
As of December 31, 2021, cash and cash equivalents were €43.3 million and turnover was €1.0 million Success of Euronext Paris IPO in November 2021 with €35.7 million capital raised, after
GenSight Biologics Reports Interim Financial Results for the First Half of 2021 and Provides Operational Update ATUs in France in Europe in H1 2022 Successful refinancing in Q1 2021 secures mid-2023 runway Multiple regulatory and clinical milestones expected in Q4 2021 Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its interim financial results for the first half of 20...
Scottsboro is stated to operate a secondary aluminum processing facility (“Facility”) in Jackson County, Alabama. The Facility includes an aluminum scrap dryer operated pursuant to the authority of Air Permit No. 705-0030-X006 (“Permit”). Emissions from the aluminum scrap dryer are stated to be controlled by a baghouse. ADEM is stated to have conducted an inspection of the Facility on September 29, 2020. The CO provides that Scottsboro was operating the aluminum scrap dryer without its associated baghouse and without temporary authorization to operate as required by certain provisions...
Advicenne Reports its Full-Year Financial Results to December 31, 2020 and Confirms its 2021 Outlook Regulatory News: Advicenne (Paris:ADVIC) (BSE:ADVIC) (Euronext: ADVIC), a French company specialized in the development of therapeutic products adapted to children and adults for treating nephrological and neurological orphan diseases, today reported its 2020 financial results. 2020 HIGHLIGHTS Scientific developments On March 10, 2020, Advicenne was authorized to make ADV7103 available within the framework of a Temporary Authorization for Use (TAU) scheme established by France's National Agen...